Inicio>>Signaling Pathways>> Antibody-drug Conjugate/ADC Related>> ADC Linker>>Propargyl-PEG8-NHS ester

Propargyl-PEG8-NHS ester

Catalog No.GC66707

Propargyl-PEG8-NHS éster es un enlazador PROTAC basado en PEG/Alkyl/ether que se puede utilizar en la síntesis de PROTAC. Propargyl-PEG8-NHS éster es un enlazador de ADC escindible que se utiliza en la síntesis de conjugados de anticuerpo-fármaco (ADC).

Products are for research use only. Not for human use. We do not sell to patients.

Propargyl-PEG8-NHS ester Chemical Structure

Cas No.: 2182601-74-5

Tamaño Precio Disponibilidad Cantidad
100mg
138,00 $
Disponible
250mg
237,00 $
Disponible
1g
620,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Propargyl-PEG8-NHS ester is a PEG/Alkyl/ether-based PROTAC linker can be used in the synthesis of PROTACs. Propargyl-PEG8-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.

[1]. Satwik Kamtekar, et al. Modified biotin-binding proteins for immobilization. WO2019126734A1.

Reseñas

Review for Propargyl-PEG8-NHS ester

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Propargyl-PEG8-NHS ester

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.